 |
| CLICK HERE TO VIEW CURRENT ISSUE |
 |
| Best of NAMA 2025 |
|
 |
|
FDA 'S APPROVAL OF PRRS RESISTANT PIG GIVES ANIMAL GENETIC FIRM GENUS PROFITS A BOOST
Jul. 17, 2025
Source: Genus news release
Basingstoke, U.K. -- Global animal genetics company Genus has published a trading update for its fiscal year ending June 30. Highlights include double digit underlying growth in PIC adjusted operating profit, with an additional net £3.7m milestone receipt following the U.S. Food and Drug Administration's approval of the gene edited PRRS Resistant Pig
PIC's underlying trading was in-line with expectations in the second half, with the Americas and Asia regions continuing to perform well. As announced on April 30, the FDA issued its landmark approval for the group's PRP to be used in the U.S. food supply chain. The approval comprised a $5.5m (£4.1m) milestone receipt from the group's Chinese partner, Beijing Capital Agribusiness, as per the terms of the strategic porcine collaboration agreement signed in May 2019, as well as Genus making milestone payments of £0.4m to its research collaborators.
ABS performed ahead of expectations in the second half, with Value Acceleration Program initiatives continuing to be the primary driver of adjusted operating profit growth. VAP Phase 2 achieved £8.5m of in-year benefit and in total the annualized benefit of VAP Phase 1 and Phase 2 is projected to be over £21m, as expected. ABS has commenced Phase 3 initiatives to reshape its go-to-market channels and enhance commercial excellence to accelerate growth.
As a result of good trading and the PRP milestone receipt, the board now expects group FY25 adjusted profit before tax to be at least £72m in actual currency. Excluding the net £3.7m PRP milestone receipt, FY25 adjusted PBT is expected to be at least £68m in actual currency, in-line with expectations.
Group cash conversion in the second half continued to be very strong resulting in strong growth in free cash flow and a reduction in leverage to less than 1.6x at year-end.
|
|
|
|
|
